Imricor Medical Systems Secures FDA Pediatric Clearance, Expanding MRI-Guided Cardiac Care Market
Imricor Medical Systems, Inc. (ASX: IMR) has secured U.S. Food and Drug Administration (FDA) 510(k) clearances expanding the approved use of its NorthStar® mapping and guidance system and Vision-MR® Diagnostic Catheter to include pediatric patients. The approvals allow both products to be used across all age groups, creating new opportunities for radiation-free interventional magnetic resonance (iMR) procedures in children and young adults. The milestone supports procedures such as cardiac catheterisations for congenital heart disease, reducing exposure to ionising radiation for vulnerable patients. With more than 250,000 diagnostic right and left heart catheterisations performed annually across adult and children's hospitals in the United States, the expanded indication significantly broadens Imricor’s addressable market. The company also believes pediatric hospitals provide an attractive entry point for commercial adoption ahead of wider deployment of its complete electrophysiology platform in adult healthcare facilities. These regulatory approvals strengthen Imricor’s U.S. commercial strategy while reinforcing its leadership in MRI-guided cardiac intervention technologies.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Imricor Medical Systems Secures FDA Pediatric Clearance, Expanding MRI-Guided Cardiac Care Market
Imricor Medical Systems, Inc. (ASX: IMR) has secured U.S. Food and Drug Administration (FDA) 510(k) clearances expanding the approved use of its NorthStar® mapping and guidance system and Vision-MR® Diagnostic Catheter to include pediatric patients. The approvals allow both products to be used across all age groups, creating new opportunities for radiation-free interventional magnetic resonance (iMR) procedures in children and young adults. The milestone supports procedures such as cardiac catheterisations for congenital heart disease, reducing exposure to ionising radiation for vulnerable patients. With more than 250,000 diagnostic right and left heart catheterisations performed annually across adult and children's hospitals in the United States, the expanded indication significantly broadens Imricor’s addressable market. The company also believes pediatric hospitals provide an attractive entry point for commercial adoption ahead of wider deployment of its complete electrophysiology platform in adult healthcare facilities. These regulatory approvals strengthen Imricor’s U.S. commercial strategy while reinforcing its leadership in MRI-guided cardiac intervention technologies.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au